The second National CARE™ Congress was a great success! 
Thank you to all those who attended.

The second National CARE™ Congress: Update on Biosimilars and Access to Innovation was held at the Shangri-La Hotel in Toronto on April 6th, 2018. The meeting addressed questions and considerations regarding biosimilars in Canada and how they build towards a larger discussion on access to innovative medicine. The meeting included discussion and provided a platform for medical specialists and key stakeholders across multiple fields to meet, collaborate, and discuss concepts that have a practical impact on the Canadian healthcare landscape.  


Date/Agenda:

Friday, April 6th, 2018
Registration & Lunch 11:15 – 12:00 pm
Meeting Sessions 12:00 – 5:00 pm

Location:

Shangri-La Hotel,
188 University Ave, Toronto, ON
Queens Park South Meeting Room

Chairs: 

John Marshall, MD – McMaster University
John Kuruvilla, MD – Princess Margaret Cancer Centre


Event Feedback

The Aim

The CARE™ Congress aims to allow assembled CARE™ faculty and panelists to consider the use of biosimilars and align on the importance of access to innovation. 

The CARE™ Faculty is pleased to welcome a robust speaker line-up, with representation from Canadian researchers, clinicians, government,  public and private funding agencies, health economists, hospital pharmacists, nurses, advocacy groups, ethicists and legal experts.

 


Section 1: Update on Biosimilars

The first section of the 2018 CARE™ Congress on Biosimilars and Access to Innovation focused on biosimilars. After an opening from the Congress Chairs, Dr. John Marshall and Scott Edwards presented on CARE™ education initiatives in biosimilars and gaps in knowledge that still exist in Canada. This was followed by a multidisciplinary discussion.

Section 2: Access to Innovation

In the second section of the 2018 CARE™ Congress, participants were involved in the following four plenary sessions on access to innovation: Translational Science & Innovation to Access, Drug Approval and Public Pricing, Private Payer Perspectives, and Patient Perspectives. Multi-stakeholder discussions took place after the first three presentations. 

Plenary Session 1:

Plenary Session 2:

Plenary Session 3:


 The following graphic depicts the drug approval, pricing and public funding process in Canada (courtesy of the pCPA).

The following graphic depicts the drug approval, pricing and public funding process in Canada (courtesy of the pCPA).


Plenary Session 4:


CARE™ receives funding from multi-industry sponsors at arm’s length. Content reflects the opinions, output and analyses of experts, investigators, educators and clinicians (“CARE™ Faculty”), whose activities, while independent, are commercially supported by the noted sponsor(s). Program content is developed independently of sponsor(s). This content is intended for educational value only; to make scientific information and opinions available to health professionals, to stimulate thought, and further investigation.